DG
CLVS

Delek Group’s Clovis Oncology, Inc. CLVS Stock Holding History

Delek Group’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-42,000
Closed -$1.23M – 254
2018
Q3 		$1.23M Hold
42,000
– – 0.05% 187
2018
Q2 		$1.91M Hold
42,000
– – 0.08% 168
2018
Q1 		$2.22M Hold
42,000
– – 0.11% 148
2017
Q4 		$2.85M Buy
+42,000
New +$2.94M 0.15% 138

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return

Delek Group's CLVS Position: Q4 2018 in Review

Delek Group sold out of Clovis Oncology, Inc. (CLVS) in Q4 2018, closing a stake of 42,000 shares — an estimated $1.23M sold.

Delek Group first reported a position in CLVS in Q4 2017 and held it in 4 quarters. The position peaked at $2.85M in Q4 2017. 165 funds tracked by Wall St. Rank hold CLVS as of Q4 2018.

  • Delek Group reported no remaining Clovis Oncology, Inc. position as of Q4 2018 after selling out during the quarter.
  • Delek Group sold 42,000 Clovis Oncology, Inc. shares in Q4 2018, an estimated $1.23M.
  • Delek Group first reported a position in Clovis Oncology, Inc. in Q4 2017 and held it in 4 quarters.
  • Delek Group's Clovis Oncology, Inc. position peaked at $2.85M in Q4 2017.
  • 165 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q4 2018.

Based on Delek Group's 13F filing for Q4 2018, filed 14 Feb 2019.